Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Shikiar Asset Management Inc.

Shikiar Asset Management Inc. lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 770 shares of the biopharmaceutical company’s stock after selling 17 shares during the period. Shikiar Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $548,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Rakuten Securities Inc. grew its position in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the last quarter. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $26,000. Fairfield Financial Advisors LTD acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $37,000. Truvestments Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $39,000. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $42,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $681.58 on Friday. The stock has a market capitalization of $74.90 billion, a P/E ratio of 16.87, a P/E/G ratio of 1.60 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm’s 50-day moving average is $741.54 and its two-hundred day moving average is $952.59.

Analysts Set New Price Targets

REGN has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Bank of America restated an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, Evercore ISI cut their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.